NKTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NKTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-10-31), Nektar Therapeutics's share price is $1.19. Nektar Therapeutics's GF Value is $1.79. Therefore, Nektar Therapeutics's Price-to-GF-Value for today is 0.66. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Nektar Therapeutics is Possible Value Trap, Think Twice.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
Nektar Therapeutics (NAS:NKTR) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Nektar Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 1.19 | / | 1.79 | |
= | 0.66 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Nektar Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Howard W Robin | director, officer: President & CEO | |
Jonathan Zalevsky | officer: Chief R&D Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Mark Andrew Wilson | officer: SVP & General Counsel | 1613 RAY DRIVE, BURLINGAME CA 94010 |
Robert Chess | director, officer: Executive Chairman | |
Myriam Curet | director | 1020 KIFER ROAD, SUNNYVALE CA 94086 |
Jeffrey Robert Ajer | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Sandra A. Gardiner | officer: Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jillian B. Thomsen | officer: VP & Chief Accounting Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Gil M Labrucherie | officer: SVP, COO & CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
John Northcott | officer: SVP & Chief Commercial Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Diana Brainard | director | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
R Scott Greer | director | 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253 |
Lutz Lingnau | director | 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945 |
Stephen K Doberstein | officer: Chief Scientific Officer | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
From GuruFocus
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 05-10-2024
By PRNewswire • 08-08-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By PRNewswire • 03-05-2024
By PRNewswire • 06-12-2024
By GuruFocus Research • 03-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.